Faculty Profile

Li hua Bao
Section of Hospital Medicine
Clinical Associate of Medicine
Referring Physician Access Line: 1-877-DOM-2730

Academic Interests

Dr. Bao’s research focuses on the role of complement activation in the pathogenesis of experimental lupus nephritis. She has found that using a Crry transgenic model or the recombinant Crry-Ig to inhibit complement activation at the level of C3 significantly prevented MRL/lpr mice from development of renal failure and proteinuria. Currently she is focusing on the potential mechanisms of these beneficial effects by examining inflammatory gene expression and signaling changes.

Clinical Interests



  • Bao L, Zhou J, Holers VM and Quigg RJ. Excessive Matrix Accumulation in the Kidneys of MRL/lpr Lupus Mice Is Dependent on Complement Activation. J Am Soc Nephrol. 2003 Oct; 14(10):2516-25.
  • Bao L, Haas M, Kraus DM, Hack BK, Rakstang JK, Holers VM and Quigg RJ. Administration of a soluble recombinant complement C3 inhibitor protects against renal disease in MRL/lpr mice. J Am Soc Nephrol. 2003 Mar;14(3):670-9
  • Alexander JJ, Saxena AK, Bao L, Jacob A, Hass M and Quigg RJ. Prominent renal expression of a murine leukemia retrovirus in experimental systemic lupus erythematosus. J Am Soc Nephrol. 2002 Dec;13(12):2869-77.
  • Bao L, Haas M, Boackle SA, Kraus DM, Cunningham PN, Park P, Alexander JJ, Anderson RK, Culhane K, Holers VM and Quigg RJ. Transgenic expression of a soluble complement inhibitor protects against renal disease and promotes survival in MRL/lpr mice. J Immunol. 2002, Apr 1;168(7):3601-7
  • Bao L, Spiller OB, St John PL, Haas M, Hack BK, Ren G, Cunningham PN, Doshi M, Abrahamson DR and Quigg RJ. Decay-accelerating factor expression in the rat kidney is restricted to the apical surface of podocytes. Kidney Int. 2002 Dec;62(6):2010-21.


  • MD, 1991, Capital Insititute of Medicine, Medicine
  • MS, 1996, Beijing Medical Univ., Nephrology
  • Residency, 2018, Texas Tech University Health Science Center, Internal Medicine